Untreated Advanced or Recurrent Thymic Carcinomas Clinical Trials in Chūō, Tokyo

First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)